Introduction: Why Nitrosamine Testing for Rifapentine Needs a Specialized Approach Nitrosamine Testing for Rifapentine is not a simple lab task. […]
Nitrosamine Testing for Rifapentine API and Finished Products Read More »
Introduction: Active Ingredient Characterization for ANDA submission is a fundamental requirement to establish that the generic product matches the reference
How to Characterize Active Ingredients in Finished Dosage Forms for ANDA Read More »
Summary: 1. Introduction A Retatrutide Sameness Study is the mandatory analytical validation required to prove that a generic synthetic peptide
The Regulatory Requirements for Long Acting Injectable Development are complex and demand a clear link between formulation design, manufacturing quality,
Introduction: Why Conventional Analytical Frameworks Fall Short for LAI Systems The Analysis of Long Acting Injectable Formulations is one of
Summary: A Tirzepatide Sameness Study is the scientific backbone of a successful generic Abbreviated New Drug Application (ANDA). This report
Introduction: The pharmaceutical industry is steadily moving away from daily oral medicines and toward advanced depot systems. This change is
Long Acting Injectable vs Oral Dosage Forms: Why Pharma is Shifting Toward Depot Systems Read More »
Introduction: A long acting injectable is only as strong as the attributes that define its performance. Critical Quality Attributes for
Introduction: Peptide Characterization for ANDA submission is a critical regulatory requirement to demonstrate that a generic peptide drug is equivalent
Peptide Characterization Requirements for ANDA Approval Read More »
Introduction: An Exenatide Sameness Study is a comprehensive analytical comparison conducted to demonstrate that a generic exenatide drug product is
